Organization
University of Toronto
2 clinical trials
98 abstracts
2 posters
Abstract
Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS).Org: Princess Margaret Cancer Centre, Department of Pathology and Laboratory Medicine, Radiation Medicine Program, Natera, Inc., University Health Network,
Abstract
Cost-utility of geriatric assessment in older adults with cancer: Results from the 5C trial.Org: Lawrence S. Bloomberg Faculty of Nursing, Turpanjian College of Health Sciences, Western University, McMaster University and Juravinski Cancer Centre, Bruyere Research Institute,
Abstract
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.Org: Massachusetts General Hospital, Department of Experimental Therapeutics, National Cancer Center Hospital East, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Memorial Sloan Kettering Cancer Center,
Abstract
ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.Org: South Australian Health and Medical Research Institute, Universitätsklinikum Jena, Akita University Hospital, The University of Texas MD Anderson Cancer Center, University of Chicago,
Abstract
Phase IB study of tovorafenib for children with relapsed/recurrent low-grade gliomas and other MAPK pathway activated tumors.Org: Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Children's Hospital of Philidelphia, St. Louis Children's Hospital, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Massachusetts General Hospital,
Abstract
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,
Abstract
Cost-utility of geriatric assessment (GA) in older adults with cancer: A model-based economic evaluation of four randomized controlled trials (RCTs).Org: University of Toronto, University Health Network, Lawrence S. Bloomberg Faculty of Nursing, Princess Margaret Cancer Centre,
Abstract
Depicting oncologists' perceptions and knowledge of global disparities in conflicts of interest reporting: The ONCOTRUST-1 study.Org: Faculty of Medical Sciences, University Mohammed VI Polytechnic, National Institute of Oncology. Istenhegyi Géndiagnosztika Private Health Center Oncology Clinic, Evercare Hospital Dhaka, Kenyatta University Teaching,
Abstract
Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor.Org: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Department of Medical Biophysics, University of Toronto,
Abstract
The impact of admitting ward on resource utilization and outcomes among hospitalized cancer survivors.Org: Princess Margaret Cancer Centre, University of Toronto, Division of General Internal Medicine, St Michael's Hospital, Unity Health - St Michael's Hospital,
Abstract
Association of socioeconomic status with aggressive end-of-life care in patients with cancer before and during the COVID-19 pandemic.Org: University Health Network (UHN), University of Toronto, Queen's University Belfast, Princess Margaret Cancer Centre, Department of Biostatistics & Data Science,
Abstract
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.Org: Penn State Milton S. Hershey Medical Center, Hershey, PA, Penn State College of Medicine, University Park, PA, University of Toronto,
Abstract
Clinical and molecular features and survival in thyroid cancer with brain metastases.Org: University of Toronto, Princess Margaret Cancer Centre, University Health Network, Princess Margaret Cancer Center, Department of Medical Oncology and Hematology,
Abstract
Development of clinically accessible nomograms to predict risk of brain metastases at baseline and follow-up in patients with non-small cell lung cancer.Org: Penn State College of Medicine, University of Toronto, John Hopkins University, Arizona College of Osteopathic Medicine, Penn State Hershey Medical Center,
Abstract
Cost-effectiveness of dabrafenib plus trametinib in BRAFV600E-mutant pediatric low-grade glioma: A microsimulation study.Org: The Hospital for Sick Children, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, University of Alberta, University of Toronto,
Abstract
Phase 2 study of bizaxofusp, an IL-4R targeted toxin payload, in nonresectable recurrent GBM: Comparison of overall survival with contemporaneous eligibility-matched and propensity score balanced external control arm.Org: Medicenna Therapeutics Inc., Hospital of the University of Pennsylvania, University of Texas Health San Antonio Cancer Center, Medicenna Therapeutics, St. Michael's Hospital and University of Toronto,
Abstract
Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.Org: Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, Department of Medical Oncology, The Sidney Kimmel Cancer Center at Johns Hopkins, Cancer Convergence Institute, Bloomberg-Kimmel Institute, Baltimore, MD, Ontario Institute for Cancer Research, Toronto, ON, Canada, Northwell Health Cancer Institute, Lake Success, NY, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD,
Abstract
A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.Org: Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Center, Toronto, ON, Canada, Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal, QC, Canada, University of Western Ontario, London, ON, Canada, Manitoba Prostate Cancer, University of Manitoba, Winnipeg, MB, Canada, CancerCare Manitoba, Winnipeg, MB, Canada, McGill University Health Center, Montreal, QC, Canada, Department of Urology, Dalhousie University, Halifax, NS, Canada, Queen's University, Kingston, ON, Canada, St. Josephs Healthcare, McMaster University, Hamilton, ON, Canada, Northern Alberta Urology Clinic, Edmonton, AB, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada, University Health Network, Toronto, ON, Canada, Ottawa Hospital, Ottawa, ON, Canada, CIUSSS de l'Estrie – CHUS (Hôpital Fleurimont), Sherbrooke, QC, Canada, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, St. Vincent's Hospital Sydney, Sydney, NSW, Australia, Princess Margaret Cancer Centre, University Health Network, Toronto Allergy and Asthma Centre, Oncotelic,
Abstract
Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy.Org: Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Department of clinical and molecular medicine, Faculty of Medicine and Health Sciences,
Abstract
A descriptive patient-reported outcomes (PROs) analysis of KEYNOTE-412 to understand head and neck symptom burden.Org: Merck & Co., Inc., Gustave Roussy Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Yale University School of Medicine, National Cancer Center Hospital East, Kashiwa, Japan,
Clinical trial
A Randomized, Double Blind, Placebo Controlled Study of Homeopathic Treatment of Children and Youth With Attention Deficit Hyperactivity DisorderStatus: Completed, Estimated PCD: 2021-03-01
Abstract
Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.Org: Princess Margaret Cancer Centre, University Health Network, University of Toronto, 23andMe, Jasper Therapeutics,
Abstract
The influence of sarcopenia and myosteatosis on severe laboratory toxicity and overall mortality in older adults with cancer receiving chemotherapy.Org: University Health Network, University of Toronto, Toronto General Hospital, Princess Margaret Cancer Centre,
Abstract
Fragility index analysis of systemic therapy clinical trials in soft tissue sarcoma (STS).Org: Princess Margaret Cancer Centre, Queen's Cancer Research Institute, Queen's University Belfast, University Health Network, University of Toronto,
Abstract
Neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer (NSCLC): A systematic review and extracted individual patient data meta-analysis.Org: Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto,
Abstract
Analysis of outcomes in resected early-stage non-small cell lung cancer (NSCLC) with rare targetable driver mutations.Org: Princess Margaret Cancer Centre, University Health Network, Department of Medical Oncology and Hematology, Division of Thoracic Surgery, Shizuoka Cancer Center, University of Toronto,
Abstract
Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada.Org: University of Calgary, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Princess Margaret Cancer Center, University Health Network, University of British Columbia,
Abstract
Safety and efficacy of interleukin-6 blockade for immune-related adverse events: A systematic review and meta-analysis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, University of Toronto,
Abstract
CSF proteomics for predicting response to treatment in patients with primary and secondary central nervous system lymphoma.Org: Penn State College of Medicine, University Park, PA, PainReform, University of Toronto, Toronto Allergy and Asthma Centre,
Abstract
Comparing the characteristics and outcomes of hospitalizations between cancer and non-cancer survivors.Org: University Health Network, Princess Margaret Cancer Centre, Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, Los Angeles, CA, St Michael's Hospital, University of Toronto,
Clinical trial
Continuous Adductor Canal Block in Outpatient Total Knee ArthroplastyStatus: Recruiting, Estimated PCD: 2024-09-03
Abstract
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.Org: DFCI/BWH Cancer Center, University of Chicago, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, Rutgers Cancer Institue of New Jersey, University of Toronto,
Abstract
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).Org: NeoGenomics Ltd, Cancer Genomics Program - Princess Margaret Cancer Centre, Laboratory Medicine Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Impact of geography on receipt of medical oncology consultation and neoadjuvant chemotherapy for triple negative and HER2 positive breast cancer.Org: University of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences Centre, ICES, Sunnybrook Odette Cancer Centre,
Abstract
Clinical outcomes and correlation with longitudinal circulating tumor (ct)DNA dynamics of a phase I/II study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced or metastatic breast cancer.Org: Princess Margaret Cancer Center, University Health Network, University of Toronto, The Ottawa Hospital Cancer Center, GSK Research and Development Upper Providence, Collegeville, PA,
Abstract
Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.Org: University of Toronto, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Centre Hospitalier Universitaire de Québec,
Abstract
Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, Toronto, ON, Canada,
Abstract
Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: A real-world analysis of outcomes, clinical and pathologic characteristics.Org: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, University of Toronto, Joint Division of Medical Imaging (JDMI),
Abstract
Imbalance in treatment discontinuation without progression between experimental and control arms among randomized trials in advanced breast cancer.Org: Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, University of British Columbia, Vancouver, BC, Canada, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, University of Victoria, Victoria, BC, Canada, Canadian Cancer Society, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Patient Partner, Toronto, ON, Canada, University of Alberta, Edmonton, AB, Canada, BC Cancer/ University of British Columbia, Vancouver, BC, Canada, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada, British Columbia Cancer Agency, Vancouver, BC, Canada, Princess Margaret Cancer Centre, University of Toronto,
Abstract
TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.Org: University of Texas MD Anderson Cancer Center, Sunnybrook Odette Cancer Centre, University of Toronto, The Ottawa Hospital and University of Ottawa, Washington University School of Medicine in St Louis,
Abstract
Toxicity reporting consistency and subjective minimizing language use in colorectal cancer (CRC) and pancreatic cancer (PaC) clinical trials: A systematic review of phase III randomized controlled trials (RCTs) presented at ASCO between 2012-2022.Org: H. Lee Moffitt Cancer Center and Research Institute, Moffitt Cancer Center and Research Institute, London Health Sciences Centre & Schulich School of Medicine, University of Toronto, Queen's University, Belfast,
Abstract
Global circulating free DNA methylation and fragmentome deconvolution in patients with metastatic renal cell carcinoma treated with immunotherapy (GOLDEN).Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada,
Abstract
Impact on turnaround times (TAT) among non-squamous non-small cell lung cancer (NSCLC) patients across three time periods with varying biomarker testing techniques.Org: University of Toronto, Institute of Health Policy, Management, and Evaluation, University Health Network, Queen's University, Belfast, Princess Margaret Cancer Centre,
Abstract
An intelligent machine learning model for real-time early detection of undesirable cancer events: AIM2REDUCE.Org: Princess Margaret Cancer Centre, Department of Computer Science, University of Toronto,
Abstract
HER2-low breast cancer brain metastases: Incidence and treatment implications.Org: University of Toronto, Sunnybrook Hospital, Toronto, ON, Canada, Sunnybrook Health Sciences Center, Department of Laboratory Medicine and Pathobiology,
Abstract
Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Princess Margaret Cancer Centre, University of Toronto,
Abstract
Tandem duplicator phenotype: A novel targetable subgroup in pancreatic cancer?Org: Princess Margaret Cancer Centre, Ontario Institute for Cancer Research, Toronto, ON, Canada, Trinity St. James’s Cancer Institute, University of Toronto, University Health Network,
Abstract
Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).Org: Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Ontario Institute for Cancer Research, Toronto, ON, Canada,
Abstract
Association of dynamic changes in serological markers with survival in de novo metastatic hormone-sensitive prostate cancer.Org: Rush University Medical Center, Case Western Reserve University School of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, UCLA Department of Radiation Oncology,
Abstract
Characterizing KRAS allele variants within biliary tract cancers.Org: Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, University of Texas MD Anderson Cancer Center,
Abstract
Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): Updated individual patient data meta-analyses from the MARCAP consortium.Org: Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, University of California Los Angeles, Alfred Health Radiation Oncology,
Abstract
Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A+B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding complications.Org: Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Tom Baker Cancer Centre,
Abstract
Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.Org: University of California, San Francisco Medical Center, University of North Carolina, Lineberger Comprehensive Cancer Center, University of Chicago, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Duke Cancer Institute,
Abstract
CCTG HN11: SPECT-CT guided elective contralateral neck treatment (SELECT) for patients with lateralized oropharyngeal cancer—A phase III randomized controlled trial.Org: University Health Network, Canadian Cancer Trials Group, CHUM - Centre Hospitalier de l'Universite de Montreal, Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), University of Toronto,
Abstract
Brain metastasis burden and management in small cell lung cancer: An analysis of 8705 patients.Org: University of Toronto, Princess Margaret Cancer Centre, Sunnybrook Odette Cancer Centre, University Health Network, St. Michael's Hospital and University of Toronto,
Abstract
Metronomic dosing of selinexor in select soft tissue sarcomas (STS).Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Evaluation of hyperprogression in patients with sarcoma treated with targeted therapy and/or immunotherapy in early-phase clinical trials.Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, The Hospital for Sick Children, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
The effect of exercise on physical function and medication adherence in women receiving endocrine therapy for breast cancer: The Breast Cancer Endocrine Therapy Fitness (BE-FIT) randomized controlled trial.Org: University of British Columbia, BC Cancer Agency Vancouver Island Centre, British Columbia Cancer Agency, University of Toronto,
Abstract
Interventions to improve outcomes for caregivers of patients with advanced cancer: A systematic review and meta-analysis.Org: Princess Margaret Cancer Centre, Toronto, ON, Canada, Kingston Health Sciences Centre, Kingston, ON, Canada, Oxford University Hospitals NHS Foundation Trust,
Abstract
Immune correlates of outcome in patients with leiomyosarcoma (LMS) treated with durvalumab plus olaparib or cediranib: Transcriptome analysis from the DAPPER study.Org: Princess Margaret Cancer Centre, University Health Network, Ontario Institute for Cancer Research, Toronto, ON, Canada, University of Toronto,
Abstract
Palliative care as a component of high-value and cost-saving care during hospitalization for metastatic cancer.Org: Suny Downstate Health Sciences University, Sunnybrook Health Sciencies, Princess Margaret Cancer Centre, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, University of Toronto,
Abstract
Real world evidence for continuing HER2-directed therapy for metastatic breast cancer.Org: BC Cancer-Vancouver Centre, B.C. Cancer Agency, University of Toronto, BC Cancer Agency Vancouver Island Centre, British Columbia Cancer Agency,
Abstract
Importance of DICER1 pathogenic variants in non-small cell lung cancer.Org: Mayo Clinic Alix School of Medicine, Caris Life Sciences, Irving, TX, McGill University Health Center, University of Toronto, Mayo Clinic Arizona, Phoenix, AZ,
Abstract
The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study.Org: Princess Margaret Cancer Centre, ICES, Ontario Health (Cancer Care Ontario), Princess Margaret - University Health Network, University Health Network,
Abstract
Intestinal microbiome characterization in immune checkpoint inhibition (ICI) resistant disease.Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Ontario Cancer Institute,
Abstract
Understanding treatment toxicity patterns through remote symptom monitoring and examining the effect of frailty in older men with metastatic prostate cancer.Org: Princess Margaret Cancer Centre, University Health Network, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Odette Cancer Centre, Sunnybrook Health Sciences Centre,
Abstract
Feasibility of daily physical activity monitoring and associations with treatment toxicity in older adults with metastatic prostate cancer.Org: University Health Network, Princess Margaret Cancer Centre, National Institute of Medical Sciences and Nutrition Salvador Zubirán, University of Toronto, Odette Cancer Centre,
Abstract
Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).Org: Schulich School of Medicine and Dentistry, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, London Regional Cancer Program, University Health Network,
Abstract
Prognostic value of human leukocyte antigen G (HLA-G) expression in solid tumors: A systematic review and meta-analysis.Org: Hospital Clinico San Carlos, IdISSC, Velindre Cancer Centre, Velindre University NHS Trust, Clinica Universidad de Navarra, Princess Margaret Cancer Centre,
Abstract
Symptom severity, specialty palliative care, and subsequent symptom control among adolescents and young adults with cancer: A population-based study.Org: Sunnybrook Health Sciences Centre, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada, ICES, Toronto, ON, Canada, Institute for Clinical Evaluative Science, Toronto, ON, Canada, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, The Hospital for Sick Children, ICES, Southlake Regional Health Centre,
Abstract
The prognostic value of degree of pre- and post-treatment anemia in patients with advanced gastroesophageal cancers.Org: University of Toronto, Princess Margaret Cancer Centre, University Health Network, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Department of Surgery, Brigham and Women's Hospital, Boston, MA,
Abstract
Education modalities for serious illness communication training: A scoping review on the impact on clinician behavior and patient outcomes.Org: Juravinski Hospital and Cancer Centre, University of Toronto, McMaster University and Juravinski Cancer Centre,
Abstract
Reflex MammaPrint testing on breast core biopsies: A single center experience.Org: University of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Sunnybrook Health Sciences Center,
Abstract
Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis.Org: Federal University of Minas Gerais - UFMG, Princess Margaret Hospital, Federal University of Amazonas - UFAM, Federal University of Pará - UFPA, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto,
Abstract
Association of socioeconomic status (SES) with use of specialist palliative care (SPC) among people who died with cancer before and during the COVID-19 pandemic.Org: University Health Network (UHN), University of Toronto, Division of Medical Oncology & Haematology, Princess Margaret Cancer Centre, UHN, Queen's University, Belfast, University of Ottawa,
Abstract
Association of COVID-19 pandemic with indolent lymphoma care delivery and outcomes in Ontario, Canada: A population-based analysis.Org: Princess Margaret Cancer Centre, University Health Network, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Toronto, Institute for Clinical Evaluative Sciences,
Abstract
Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study.Org: Ontario Clinical Oncology Group, McMaster University and Juravinski Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto,
Abstract
Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).Org: Cerba Research, Montpellier Cancer Institute, France, Montreal, QC Kinetix,
Abstract
Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: Real-world evidence.Org: Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Dermatology,
Abstract
Prophylactic cranial irradiation in small cell lung cancer patients in the era of magnetic resonance imaging: A systematic review and meta-analysis.Org: University of Toronto, Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Princess Margaret Cancer Centre, University Health Network,
Abstract
Prognostic effects of TP53 variants co-occuring in patients with HER2-mutated non-small cell lung cancer (NSCLC).Org: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Center, University of Toronto,
Abstract
ATTRITION AND PARTICIPANT CHARACTERISTICS IN A RHEUMATOID ARTHRITIS COHORT Org: Ontario Best Practices Research Initiative, University of Toronto, Research Institute, University Health Network, Toronto, Canada,
Abstract
A SYSTEMATIC REVIEW AND QUALITY APPRAISAL OF GUIDELINES ON THE PHARMACOLOGICAL TREATMENT OF RHEUMATOID ARTHRITIS Org: University of Calgary, Calgary, University of Toronto, Mount Sinai Hospital, Toronto, Canada,
Abstract
ADALIMUMAB IN COMBINATION WITH NON-METHOTREXATE CONVENTIONAL SYNTHETIC DISEASE MODIFYING RHEUMATIC DRUGS IN A CLINICAL TRIAL SETTING Org: Mount Sinai Hospital, University of Toronto, AbbVie, Inc., North Chicago, United States of America, North Chicago, IL, Albany School of Medicine,
Abstract
ASSOCIATION OF GENES INVOLVED IN ANTIGEN PRESENTATION AND PROCESSING IN ASOrg: University of Alberta, University of Toronto, Memorial University of Newfoundland,
Abstract
ADALIMUMAB (HUMIRA®) SUSTAINS INHIBITION OF JOINT DAMAGE FOR MORE THAN 2 YEARS IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA)Org: Seattle Rheumatology Associates, University of Washington and Fred Hutchinson Cancer Research Centre, University of Washington School of Medicine, Abbott, University of Rochester Medical School,
Abstract
A VALIDATION OF CURRENT CLASSIFICATION CRITERIA FOR THE DIAGNOSIS OF PSORIATIC ARTHRITIS – PRELIMINARY RESULTS OF THE CASPAR STUDYOrg: Medicine and Frontier Science Center of Disease Molecular Network, Wellington School of Medicine, Wellington, New Zealand, Academic Unit of Musculoskeletal and Rehabilitation Medicine, University of Leeds,
Abstract
ASSOCIATION BETWEEN METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) GENE POLYMORPHISM AND METHOTREXATE TOXICITY IN KOREAN PATIENTS WITH RHEUMATOID ARTHRITISOrg: The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea, Republic of, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Department of Nutritional Sciences, University of Toronto,
Abstract
ANALYSIS OF INTEGRATED RADIOGRAPHIC DATA FOR TWO LONG-TERM, OPEN-LABEL EXTENSION STUDIES OF ADALIMUMAB Org: Leiden University Medical Center, Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, University of Toronto, Abbott,
Abstract
A DESCRIPTIVE ANALYSIS OF LONGITUDINAL CHANGES IN RELATIVE MARKET SHARE PROPORTIONS OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS: DATA FROM THE OBRI DATABASEOrg: McMaster University and Juravinski Cancer Centre, Toronto General Hospital Research Institute, JSS Medical Research, Western University, University of Toronto,
Abstract
ASSOCIATION OF LUNG IMAGING PATTERN WITH PROGNOSIS AND IMMUNOSUPPRESSION RESPONSE IN CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASEOrg: McGill University Health Center, Saint James Hospital, McMaster University and Juravinski Cancer Centre, University of Montreal, University of Calgary,
Abstract
Assessment of the psychometric properties of patient-reported outcomes of depression in SLEOrg: Medicine, Kuopio University Hospital, Kuopio, Queen’s University and Kingston Health Science Center, Kingston, ON, Canada, Kingston, Ontario Department of Psychiatry Psychiatry, University of Toronto Toronto Western Hospital Rheumatology,
Abstract
ADALIMUMAB TREATMENT EFFECTS ON RADIOGRAPHIC PROGRESSION OF JOINT DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM ADEPTOrg: Swedish Medical Center, University of Washington School of Medicine, Southwest Medical Imaging, Department of Medicine, University of Alberta, Alberta, Canada, University of Toronto,
Abstract
AN EVALUATION OF FLARE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS USING THE OMERACT PRELIMINARY FLARE QUESTIONNAIRE Org: University of Toronto, McGill Univeristy, Cardiff University School of Medicine, University of Sherbrooke, Univeristy of Manitoba,
Abstract
ASSOCIATIONS BETWEEN DISEASE ACTIVITY, PHYSICAL FUNCTION AND ANTI-RHEUMATIC MEDICATIONS WITH ALL-CAUSE MORTALITY IN RHEUMATOID ARTHRITIS (RA): DATA FROM A CANADIAN RA REGISTRYOrg: Toronto General Hospital Research Institute, OBRI, University of Toronto, University of Ottawa, University of Western Ontario,
Abstract
ANTI-TNF THERAPY FOR IMMUNE MEDIATED INFLAMMATORY DISEASES MAY BE ASSOCIATED WITH LOWER ANTIBODY LEVELS AND VIRUS NEUTRALIZATION EFFICACY FOLLOWING SARS-CoV-2 mRNA VACCINATIONOrg: University Health Network, Schroeder Arthritis Institute, Rheumatology, Toronto, Canada, University of Toronto, Division Of Rheumatology, Department Of Internal Medicine, Toho University School Of Medicine, Tokyo, Japan, Department of Medicine, University of Alberta, Alberta, Canada,
Abstract
ANTIBODY CLUSTERING IN PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUSOrg: Hospital for Sick Children, University of Toronto, Department of Biochemistry & Molecular Biology, University of Calgary,
Abstract
BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITISOrg: Bristol Myers Squibb, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, United States of America, Medical University of Vienna, University of Rochester Medical Center, University of Toronto,
Abstract
BASELINE CHARACTERISTICS OF PATIENTS RECEIVING BIOLOGIC AND TRADITIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUG (DMARD) THERAPY IN ONTARIO: RESULTS FROM THE ONTARIO BIOLOGICS RESEARCH INITIATIVE Org: University of Toronto, University Health Network, Division of Clinical Epidemiology, Research Institute of the McGill Univ. Health, Montreal, Canada, McGill University Health Center, McMaster University and Juravinski Cancer Centre,
Abstract
BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDYOrg: Genomics England, Charité – Universitätsmedizin Berlin, Ghent University and VIB Centre for Inflammation Research, University of Toronto, Shanghai Changzheng Hospital,